TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lung Imaging for Ventilatory Setting in ARDS
Brief Summary: To compare in ARDS patients 2 ventilatory Strategies : One based on Lung Morphology (Focal versus non-Focal ARDS) versus ARDS networks Guidelines (PEEP based on FiO2). In Focal ARDS prone position will be promote early, with low PEEP and moderate Vt. In non-Focal ARDS, Recruitment maneuvers, high PEEP and low V twill be used.

The investigators made the hypothesis that ventilation according to Lung morphology my decrease mortality at D90.


Options:
A: Arm Label: One Group; Type: N/A; Interventions: N/A
B: Arm Label: prone position; Type: ACTIVE_COMPARATOR; Interventions: Procedure: prone positioning | Arm Label: supine position; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: prone positioning; Assigned to Arm(s): prone position
C: Arm Label: Focal ARDS; Type: EXPERIMENTAL; Interventions: Procedure: Mechanical ventilation | Arm Label: non focal ARDS; Type: OTHER; Interventions: Procedure: Mechanical ventilation | Intervention Type: PROCEDURE; Name: Mechanical ventilation; Assigned to Arm(s): Focal ARDS, non focal ARDS
D: Arm Label: Conventional Ventilation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Lung Protective Ventilation | Arm Label: High Frequency Oscillation; Type: EXPERIMENTAL; Interventions: Device: SensorMedics 3100B High Frequency Oscillatory Ventilator | Intervention Type: DEVICE; Name: SensorMedics 3100B High Frequency Oscillatory Ventilator; Assigned to Arm(s): High Frequency Oscillation | Intervention Type: PROCEDURE; Name: Lung Protective Ventilation; Assigned to Arm(s): Conventional Ventilation

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparison of Safety and Efficacy of Dl-3-n-butylphthalide and Cerebrolysin on Neurological and Behavioral Outcomes in Acute Ischemic Stroke: a Randomized, Double-blind Study.
Brief Summary: The investigators conducted a randomized, double-blind, trial enrolled 60 patients within 12 hours of acute ischemic stroke (AIS) in China. Patients were randomly assigned to receive a 10-day infusion of dl-3-n-butylphthalide (NBP) or cerebrolysin, or placebo. National Institutes of Health Stroke Scale (NIHSS) and Barthel Index (BI) were used to evaluate the efficacy in the patients with AIS at 11-day and 21-day after therapy. Adverse events were also analyzed among the three groups.


Options:
A: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution
B: Arm Label: Study Group 1; Type: EXPERIMENTAL; Interventions: Drug: porcine brain peptide (Cerebrolysin) | Arm Label: Study Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: porcine brain peptide (Cerebrolysin); Assigned to Arm(s): Study Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Study Group 2
C: Intervention Type: DRUG; Name: NXY-059; Assigned to Arm(s): N/A
D: Arm Label: Dl-3-n-butylphthalide; Type: EXPERIMENTAL; Interventions: Drug: Dl-3-n-butylphthalide | Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dl-3-n-butylphthalide; Assigned to Arm(s): Dl-3-n-butylphthalide | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparison of Safety and Efficacy of Dl-3-n-butylphthalide and Cerebrolysin on Neurological and Behavioral Outcomes in Acute Ischemic Stroke: a Randomized, Double-blind Study.
Brief Summary: The investigators conducted a randomized, double-blind, trial enrolled 60 patients within 12 hours of acute ischemic stroke (AIS) in China. Patients were randomly assigned to receive a 10-day infusion of dl-3-n-butylphthalide (NBP) or cerebrolysin, or placebo. National Institutes of Health Stroke Scale (NIHSS) and Barthel Index (BI) were used to evaluate the efficacy in the patients with AIS at 11-day and 21-day after therapy. Adverse events were also analyzed among the three groups.


Options:
A: Arm Label: Dl-3-n-butylphthalide; Type: EXPERIMENTAL; Interventions: Drug: Dl-3-n-butylphthalide | Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dl-3-n-butylphthalide; Assigned to Arm(s): Dl-3-n-butylphthalide | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: NXY-059; Assigned to Arm(s): N/A
C: Arm Label: Study Group 1; Type: EXPERIMENTAL; Interventions: Drug: porcine brain peptide (Cerebrolysin) | Arm Label: Study Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: porcine brain peptide (Cerebrolysin); Assigned to Arm(s): Study Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Study Group 2
D: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparison of Safety and Efficacy of Dl-3-n-butylphthalide and Cerebrolysin on Neurological and Behavioral Outcomes in Acute Ischemic Stroke: a Randomized, Double-blind Study.
Brief Summary: The investigators conducted a randomized, double-blind, trial enrolled 60 patients within 12 hours of acute ischemic stroke (AIS) in China. Patients were randomly assigned to receive a 10-day infusion of dl-3-n-butylphthalide (NBP) or cerebrolysin, or placebo. National Institutes of Health Stroke Scale (NIHSS) and Barthel Index (BI) were used to evaluate the efficacy in the patients with AIS at 11-day and 21-day after therapy. Adverse events were also analyzed among the three groups.


Options:
A: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution
B: Arm Label: Dl-3-n-butylphthalide; Type: EXPERIMENTAL; Interventions: Drug: Dl-3-n-butylphthalide | Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dl-3-n-butylphthalide; Assigned to Arm(s): Dl-3-n-butylphthalide | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Study Group 1; Type: EXPERIMENTAL; Interventions: Drug: porcine brain peptide (Cerebrolysin) | Arm Label: Study Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: porcine brain peptide (Cerebrolysin); Assigned to Arm(s): Study Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Study Group 2
D: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparison of Safety and Efficacy of Dl-3-n-butylphthalide and Cerebrolysin on Neurological and Behavioral Outcomes in Acute Ischemic Stroke: a Randomized, Double-blind Study.
Brief Summary: The investigators conducted a randomized, double-blind, trial enrolled 60 patients within 12 hours of acute ischemic stroke (AIS) in China. Patients were randomly assigned to receive a 10-day infusion of dl-3-n-butylphthalide (NBP) or cerebrolysin, or placebo. National Institutes of Health Stroke Scale (NIHSS) and Barthel Index (BI) were used to evaluate the efficacy in the patients with AIS at 11-day and 21-day after therapy. Adverse events were also analyzed among the three groups.


Options:
A: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution
B: Arm Label: Dl-3-n-butylphthalide; Type: EXPERIMENTAL; Interventions: Drug: Dl-3-n-butylphthalide | Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dl-3-n-butylphthalide; Assigned to Arm(s): Dl-3-n-butylphthalide | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: NXY-059; Assigned to Arm(s): N/A
D: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Postoperative Myocardial Injury and Non-cardiac Complications After Major Abdominal Surgery in Patients at Risk for Coronary Artery Disease
Brief Summary: To determine whether perioperative myocardial injury is associated with adverse outcome in patients scheduled for major abdominal surgery.


Options:
A: N/A
B: Intervention Type: PROCEDURE; Name: Elective colon cancer surgery; Assigned to Arm(s): N/A
C: N/A
D: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of Patterns of Patient-reported Outcomes in Adults With Congenital Heart Disease - International Study
Brief Summary: The purpose of this study is to examine the differences in perceived health, psychosocial functioning, behavioral outcomes and quality of life of adults with congenital heart disease who are living in different areas of the world, and how these differences can be understood (e.g., differences in sense of coherence or illness perceptions).


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Rehabilitaiton; Type: ACTIVE_COMPARATOR; Interventions: Other: Cardiac rehabilitation | Intervention Type: OTHER; Name: Cardiac rehabilitation; Assigned to Arm(s): Rehabilitaiton
B: Arm Label: Adults with congenital heart disease; Type: N/A; Interventions: N/A
C: Arm Label: Intervention group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Respiratory muscle training | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Respiratory muscle training; Assigned to Arm(s): Intervention group
D: Arm Label: Congenital Heart Disease; Type: N/A; Interventions: N/A | Arm Label: Healthy children; Type: N/A; Interventions: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Mental Health Outcomes: Building an Adaptive Implementation
Brief Summary: The overarching goal of this study is to build the most cost-effective adaptive implementation intervention involving a site-level implementation intervention strategy: Replicating Effective Programs (REP), and the augmentation of REP using either External Facilitation or a combination of an External and Internal Facilitation to improve patient outcomes and the uptake of an evidence-based program for mood disorders (Life Goals-LG) in community settings.


Options:
A: Arm Label: Collaborative shared care; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative shared care | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Collaborative shared care | Intervention Type: BEHAVIORAL; Name: Collaborative shared care; Assigned to Arm(s): Collaborative shared care, Usual care
B: Arm Label: REP + EF; Type: EXPERIMENTAL; Interventions: Behavioral: External Facilitation | Arm Label: REP + EF/IF; Type: EXPERIMENTAL; Interventions: Behavioral: External + Internal Facilitation | Intervention Type: BEHAVIORAL; Name: External Facilitation; Assigned to Arm(s): REP + EF | Intervention Type: BEHAVIORAL; Name: External + Internal Facilitation; Assigned to Arm(s): REP + EF/IF
C: Arm Label: Collaborative Stepped Care; Type: EXPERIMENTAL; Interventions: Other: Collaborative Stepped Care Intervention | Arm Label: Enhanced Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Enhanced Usual Care | Intervention Type: OTHER; Name: Collaborative Stepped Care Intervention; Assigned to Arm(s): Collaborative Stepped Care | Intervention Type: OTHER; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care
D: Arm Label: Arm 1 Telemedicine Outreach for PTSD; Type: EXPERIMENTAL; Interventions: Other: Telemedicine Outreach for PTSD | Arm Label: Arm 2 Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Telemedicine Outreach for PTSD; Assigned to Arm(s): Arm 1 Telemedicine Outreach for PTSD

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Home and Community Management of Fevers/Malaria and Pneumonia in Children Under-five: a Cluster Randomised Controlled Trial of an Integrated Approach in a Rural District of Burkina Faso
Brief Summary: A well-implemented community-based program of early and appropriate treatment of fevers/malaria episodes and pneumonia,will improve child survival as measured by a reduction of the less than five mortality rate.


Options:
A: Arm Label: nothing at home level; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home management of malaria; Type: EXPERIMENTAL; Interventions: Other: home/community case management | Arm Label: Home management of malaria and pneumonia; Type: EXPERIMENTAL; Interventions: Other: home/community case management | Intervention Type: OTHER; Name: home/community case management; Assigned to Arm(s): Home management of malaria, Home management of malaria and pneumonia
B: Arm Label: rapid diagnostic test; Type: ACTIVE_COMPARATOR; Interventions: Device: Rapid diagnostic test, Drug: Lumartem | Arm Label: Presumptive malaria treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Rapid diagnostic test; Assigned to Arm(s): rapid diagnostic test | Intervention Type: DRUG; Name: Lumartem; Assigned to Arm(s): rapid diagnostic test
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Rapid diagnostic test for malaria | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Rapid diagnostic test for malaria | Intervention Type: DEVICE; Name: Rapid diagnostic test for malaria; Assigned to Arm(s): 1, 2
D: Arm Label: ICCM delivered by VHT; Type: ACTIVE_COMPARATOR; Interventions: Other: ICCM delivered by VHT | Arm Label: ICCM delivered by VHT with cell phone; Type: ACTIVE_COMPARATOR; Interventions: Other: ICCM delivered by VHT, Other: ICCM delivered by VHT with Cell Phone | Arm Label: Health outcomes in communities with no ICCM; Type: ACTIVE_COMPARATOR; Interventions: Other: No intervention | Intervention Type: OTHER; Name: ICCM delivered by VHT; Assigned to Arm(s): ICCM delivered by VHT, ICCM delivered by VHT with cell phone | Intervention Type: OTHER; Name: ICCM delivered by VHT with Cell Phone; Assigned to Arm(s): ICCM delivered by VHT with cell phone | Intervention Type: OTHER; Name: No intervention; Assigned to Arm(s): Health outcomes in communities with no ICCM

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Home and Community Management of Fevers/Malaria and Pneumonia in Children Under-five: a Cluster Randomised Controlled Trial of an Integrated Approach in a Rural District of Burkina Faso
Brief Summary: A well-implemented community-based program of early and appropriate treatment of fevers/malaria episodes and pneumonia,will improve child survival as measured by a reduction of the less than five mortality rate.


Options:
A: Arm Label: ICCM delivered by VHT; Type: ACTIVE_COMPARATOR; Interventions: Other: ICCM delivered by VHT | Arm Label: ICCM delivered by VHT with cell phone; Type: ACTIVE_COMPARATOR; Interventions: Other: ICCM delivered by VHT, Other: ICCM delivered by VHT with Cell Phone | Arm Label: Health outcomes in communities with no ICCM; Type: ACTIVE_COMPARATOR; Interventions: Other: No intervention | Intervention Type: OTHER; Name: ICCM delivered by VHT; Assigned to Arm(s): ICCM delivered by VHT, ICCM delivered by VHT with cell phone | Intervention Type: OTHER; Name: ICCM delivered by VHT with Cell Phone; Assigned to Arm(s): ICCM delivered by VHT with cell phone | Intervention Type: OTHER; Name: No intervention; Assigned to Arm(s): Health outcomes in communities with no ICCM
B: Arm Label: Screening by community health workers; Type: ACTIVE_COMPARATOR; Interventions: Other: Active comparator: Screening by community health workers | Arm Label: Screening by mothers; Type: EXPERIMENTAL; Interventions: Other: Screening by mothers | Intervention Type: OTHER; Name: Screening by mothers; Assigned to Arm(s): Screening by mothers | Intervention Type: OTHER; Name: Active comparator: Screening by community health workers; Assigned to Arm(s): Screening by community health workers
C: Arm Label: Integrated mental health in primary care; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated mental health in primary care | Arm Label: Psychiatric nurse-led specialist care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychiatric nurse-led specialist care | Intervention Type: BEHAVIORAL; Name: Integrated mental health in primary care; Assigned to Arm(s): Integrated mental health in primary care | Intervention Type: BEHAVIORAL; Name: Psychiatric nurse-led specialist care; Assigned to Arm(s): Psychiatric nurse-led specialist care
D: Arm Label: nothing at home level; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home management of malaria; Type: EXPERIMENTAL; Interventions: Other: home/community case management | Arm Label: Home management of malaria and pneumonia; Type: EXPERIMENTAL; Interventions: Other: home/community case management | Intervention Type: OTHER; Name: home/community case management; Assigned to Arm(s): Home management of malaria, Home management of malaria and pneumonia

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Open Label, Randomized Study of AZD9291 Versus Platinum-Based Doublet Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose Tumours Harbour a T790M Mutation Within the Epidermal Growth Factor Receptor Gene (AURA3).
Brief Summary: A Phase III, Open Label, Randomized Study of Osimertinib versus Platinum-Based Doublet Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours harbour a T790M mutation within the Epidermal Growth Factor Receptor Gene


Options:
A: Arm Label: Osimertinib; Type: EXPERIMENTAL; Interventions: Drug: Chemotherapy, Drug: Cross-over to Osimertinib | Arm Label: Platinum-based doublet chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy | Intervention Type: DRUG; Name: Chemotherapy; Assigned to Arm(s): Osimertinib, Platinum-based doublet chemotherapy | Intervention Type: DRUG; Name: Cross-over to Osimertinib; Assigned to Arm(s): Osimertinib
B: Arm Label: Icotinib; Type: EXPERIMENTAL; Interventions: Drug: Icotinib | Arm Label: Gefitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gefitinib | Intervention Type: DRUG; Name: Icotinib; Assigned to Arm(s): Icotinib | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): Gefitinib
C: Intervention Type: DRUG; Name: gefitinib; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A
D: Arm Label: Pemetrexed + Cisplatin + Gefitinib; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed, Drug: Cisplatin, Drug: Gefitinib | Arm Label: Gefitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gefitinib | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Pemetrexed + Cisplatin + Gefitinib | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Pemetrexed + Cisplatin + Gefitinib | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): Pemetrexed + Cisplatin + Gefitinib | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): Gefitinib

Answer: A